Literature DB >> 2839749

Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method.

A Nonomura1, G Ohta, Y Nakanuma, R Izumi, Y Mizukami, F Matsubara, M Hayashi, K Watanabe, N Takayanagi.   

Abstract

Expression of the epidermal growth factor (EGF), EGF receptor (EGF-R) and ras oncogene product p21 was simultaneously examined in 37 cases with intrahepatic cholangiocarcinoma (CC) by means of an immunocytochemical method. While normal livers were all negative for any of the antigens at the concentration of the antibodies used, EGF-R was positive in 12 (32.4%) CCs, EGF in 22 (59.5%), and ras p21 in 33 (89.2%). The positive incidence of the three antigens was not different among the histologic subtypes of the tumor. However, the number of EGF-R- and ras p21-positive tumor cells decreased with progressing histologic tumor grade, but the expression of EGF was not associated with the tumor grade. Expression of the three antigens was not related to the degree of metastatic spread of the tumor. Simultaneous expression of the three antigens was seen only in 4 CCs, and that of EGF-R and EGF in 4, EGF-R and ras p21 in 12, and EGF and ras p21 in 20. These data suggest that the expression of EGF, EGF-R and ras p21 on CC cells is not related to the tumor aggressiveness, and the activation of each respective gene is independent. Furthermore, the data also indicate that an autocrine model for tumor growth, as suggested by a combination of EGF and EGF-R, may be applicable only to very limited cases of CCs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839749     DOI: 10.1111/j.1600-0676.1988.tb00985.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  13 in total

Review 1.  Progression of targeted therapy in advanced cholangiocarcinoma.

Authors:  Yingying Huang; Xiaomei Li; Yunbo Zhao
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 2.  Immunotherapy of biliary tract cancer.

Authors:  Yi Chai
Journal:  Tumour Biol       Date:  2016-01-04

3.  NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia.

Authors:  A E Sirica; S Radaeva; N Caran
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

4.  Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.

Authors:  Ling Xu; Martin Hausmann; Wolfgang Dietmaier; Silvia Kellermeier; Theresa Pesch; Manuela Stieber-Gunckel; Elisabeth Lippert; Frank Klebl; Gerhard Rogler
Journal:  BMC Cancer       Date:  2010-06-18       Impact factor: 4.430

Review 5.  AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma.

Authors:  K J Schmitz; H Lang; J Wohlschlaeger; G C Sotiropoulos; H Reis; K W Schmid; H A Baba
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 6.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

7.  Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study.

Authors:  S C Henzen-Logmans; M E van der Burg; J A Foekens; P M Berns; R Brussée; J H Fieret; J G Klijn; S Chadha; C J Rodenburg
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life.

Authors:  Ryutaro Asano; Noriaki Koyama; Yasuyo Hagiwara; Yosuke Masakari; Ryota Orimo; Kyoko Arai; Hiromi Ogata; Shozo Furumoto; Mitsuo Umetsu; Izumi Kumagai
Journal:  FEBS Open Bio       Date:  2016-05-16       Impact factor: 2.693

Review 9.  The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.

Authors:  Abigail Zabron; Robert J Edwards; Shahid A Khan
Journal:  Dis Model Mech       Date:  2013-03       Impact factor: 5.758

10.  Targeted therapy for biliary tract cancer.

Authors:  Junji Furuse; Takuji Okusaka
Journal:  Cancers (Basel)       Date:  2011-05-03       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.